Loading
A phase 2 trial of Rilvegostomig, CAPOX (capecitabine, oxaliplatin) and Capecitabine in gastric & gastro-oesophageal junction cancer, run by AstraZeneca, now recruiting.
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma is a phase 2 interventional study registered as NCT05702229 by AstraZeneca, with 163 participants planned, started 2023-01-16 and due to reach its primary completion in 2027-11-30. Interventions recorded: Rilvegostomig, Volrustomig, FOLFOX, XELOX, AZD0901 and 5-Fluorouracil.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Rilvegostomig, T-cell exhaustion and CAR-T persistence, AstraZeneca and the tag pipeline.
Shares Rilvegostomig, T-cell exhaustion and CAR-T persistence, AstraZeneca and the tag pipeline.
Shares Rilvegostomig, T-cell exhaustion and CAR-T persistence, Capecitabine, AstraZeneca and the tag pipeline.
Shares Rilvegostomig, T-cell exhaustion and CAR-T persistence, Capecitabine, AstraZeneca and the tag pipeline.
Shares Rilvegostomig, T-cell exhaustion and CAR-T persistence, AstraZeneca and the tag pipeline.
Shares Rilvegostomig, T-cell exhaustion and CAR-T persistence, Capecitabine, AstraZeneca and the tag pipeline.
Shares T-cell exhaustion and CAR-T persistence, AstraZeneca, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Rilvegostomig, T-cell exhaustion and CAR-T persistence, Capecitabine, AstraZeneca and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/